BRPI0907077A2 - métodos e composições para administração oral de proteínas - Google Patents

métodos e composições para administração oral de proteínas

Info

Publication number
BRPI0907077A2
BRPI0907077A2 BRPI0907077A BRPI0907077A BRPI0907077A2 BR PI0907077 A2 BRPI0907077 A2 BR PI0907077A2 BR PI0907077 A BRPI0907077 A BR PI0907077A BR PI0907077 A BRPI0907077 A BR PI0907077A BR PI0907077 A2 BRPI0907077 A2 BR PI0907077A2
Authority
BR
Brazil
Prior art keywords
proteins
compositions
methods
oral administration
oral
Prior art date
Application number
BRPI0907077A
Other languages
English (en)
Inventor
Kidron Miriam
Original Assignee
Oramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oramed Ltd filed Critical Oramed Ltd
Publication of BRPI0907077A2 publication Critical patent/BRPI0907077A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0907077A 2008-03-26 2009-02-26 métodos e composições para administração oral de proteínas BRPI0907077A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6477908P 2008-03-26 2008-03-26
PCT/IL2009/000223 WO2009118722A2 (en) 2008-03-26 2009-02-26 Methods and compositions for oral administration of proteins

Publications (1)

Publication Number Publication Date
BRPI0907077A2 true BRPI0907077A2 (pt) 2016-07-26

Family

ID=41114402

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907077A BRPI0907077A2 (pt) 2008-03-26 2009-02-26 métodos e composições para administração oral de proteínas

Country Status (11)

Country Link
US (3) US10058593B2 (pt)
EP (2) EP2279244B1 (pt)
JP (1) JP5395160B2 (pt)
CN (1) CN102037121B (pt)
AU (1) AU2009230718B2 (pt)
BR (1) BRPI0907077A2 (pt)
CA (3) CA3083198A1 (pt)
NZ (1) NZ588603A (pt)
RU (1) RU2504373C2 (pt)
WO (1) WO2009118722A2 (pt)
ZA (1) ZA201007522B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007029238A2 (en) 2005-09-06 2007-03-15 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
NZ588603A (en) 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
US20110046053A1 (en) * 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
BR112012021445B8 (pt) 2010-02-25 2022-07-05 Evonik Roehm Gmbh formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade
CN103003296A (zh) 2010-07-09 2013-03-27 阿菲博迪公司 多肽
EP3260131A1 (en) * 2012-01-03 2017-12-27 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
CN113769074A (zh) * 2012-02-01 2021-12-10 奥拉姆德有限公司 含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
WO2014048977A1 (en) 2012-09-25 2014-04-03 Affibody Ab Albumin binding polzpeptide
WO2014106846A2 (en) * 2013-01-03 2014-07-10 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
JP2016524617A (ja) * 2013-05-30 2016-08-18 ノヴォ ノルディスク アー／エス 糖尿病の治療のための新規な経口医薬組成物
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
CN104922682A (zh) * 2014-03-20 2015-09-23 中国科学院大连化学物理研究所 一种胰蛋白酶抑制剂及其应用
US10220076B2 (en) 2014-05-15 2019-03-05 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2023038450A1 (ko) * 2021-09-07 2023-03-16 (주)디앤디파마텍 거대 생리활성 물질 및 부형제를 포함하는 약학 조성물
CN113230386B (zh) * 2021-03-07 2022-04-12 合肥天汇孵化科技有限公司 胸腺法新组合物及其用途
WO2023017537A1 (en) * 2021-08-12 2023-02-16 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition
WO2025147459A1 (en) * 2024-01-04 2025-07-10 Nano Precision Medical, Inc. Stabilization of peptides and proteins in implantable devices and formulations
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja) 1986-08-20 1988-03-03 株式会社東芝 高速増殖炉の崩壊熱除去システム
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
ES2045276T3 (es) 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
JPH02250823A (ja) 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US6692766B1 (en) * 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
ATE493998T1 (de) * 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
JPH10330287A (ja) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
JP2000050793A (ja) 1998-08-07 2000-02-22 Meiji Milk Prod Co Ltd 人工乳組成物
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
CZ20021186A3 (cs) 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en) * 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko) 2001-03-08 2001-07-25 서종수 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
KR20010069433A (ko) 2001-03-22 2001-07-25 김윤완 노루궁뎅이버섯을 이용한 건강 보조 식품
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
AU2002316717B8 (en) 2001-07-18 2005-09-29 Solae Holdings Llc High protein, Bowman-Birk Inhibitor Concentrate and process for its manufacture
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2563533C (en) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
RU2527893C2 (ru) * 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
WO2007029238A2 (en) 2005-09-06 2007-03-15 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) * 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) 2006-06-30 2011-11-16 北京民海生物科技有限公司 一种包含稳定剂的Exendin-4注射剂药物配方
US20110166228A1 (en) 2006-11-01 2011-07-07 Anne Kristin Holmeide Composition
PL2144618T5 (pl) 2007-03-28 2025-07-21 Aker Biomarine Human Ingredients As Bio-skuteczne kompozycje oleju z kryla
NZ588603A (en) 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
US20110046053A1 (en) 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20110092592A1 (en) 2008-06-13 2011-04-21 Takashi Yano Diagnosis and treatment of hepatic disorder
US20090312302A1 (en) 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
US20110105510A1 (en) 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
UY32177A (es) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
BRPI1015120B8 (pt) 2009-05-08 2022-02-15 Basf As Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico
US20120202849A1 (en) 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
BR112012016232A2 (pt) 2009-12-30 2017-03-07 Solae Llc processo para separação e purificação de um produto de kti
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
EP2590631B1 (en) 2010-07-06 2016-10-26 Janssen Pharmaceutica NV Formulation for co-therapy treatment of diabetes
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
EP3260131A1 (en) 2012-01-03 2017-12-27 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
CN113769074A (zh) 2012-02-01 2021-12-10 奥拉姆德有限公司 含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法
WO2014106846A2 (en) 2013-01-03 2014-07-10 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
IL241462A0 (en) * 2015-09-10 2015-11-30 Yeda Res & Dev Heterologous engineering of betalain pigments in plants

Also Published As

Publication number Publication date
WO2009118722A3 (en) 2010-03-11
CN102037121A (zh) 2011-04-27
EP3777831A1 (en) 2021-02-17
CA3083698A1 (en) 2009-10-01
US10881714B2 (en) 2021-01-05
EP2279244A4 (en) 2013-11-20
RU2010141292A (ru) 2012-05-10
AU2009230718B2 (en) 2013-07-11
US10058593B2 (en) 2018-08-28
CA3083198A1 (en) 2009-10-01
EP2279244B1 (en) 2020-07-01
JP2011515458A (ja) 2011-05-19
EP3777831B1 (en) 2023-11-29
CN102037121B (zh) 2013-07-10
AU2009230718A1 (en) 2009-10-01
CA2719272A1 (en) 2009-10-01
US11660327B2 (en) 2023-05-30
US20210113663A1 (en) 2021-04-22
US20110014247A1 (en) 2011-01-20
JP5395160B2 (ja) 2014-01-22
US20180369339A1 (en) 2018-12-27
RU2504373C2 (ru) 2014-01-20
EP2279244A2 (en) 2011-02-02
ZA201007522B (en) 2012-12-27
NZ588603A (en) 2012-03-30
CA2719272C (en) 2020-08-18
WO2009118722A2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
BRPI0907077A2 (pt) métodos e composições para administração oral de proteínas
BRPI0908292A2 (pt) "métodos e composições para administração oral de exenatida"
EP2331072B8 (en) Methods and compositions for oral administration of proteins
CY2019013I1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
IL252119B (en) Improved cell composition and methods of making the same
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0923836A2 (pt) Composições farmacêuticas orais contendo opióide e métodos
IL211099A0 (en) Formulation for oral administration of proteins
HRP20161312T1 (hr) Postupak za pripravu farmaceutske formulacije kontrastnih sredstava
PT2542268T (pt) Composição sólida para administração oral de corantes e utilização desta
BRPI0907186A2 (pt) Composições proteicas pulverizadas e métodos para sua produção
PL3178490T3 (pl) Kompozycje białka f rsv i sposoby ich wytwarzania
BR112012014962A2 (pt) métodos e composições para formulações líquidas e estáveis de fármacos
BRPI0906980A2 (pt) Composição de derivados e maleatados
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
SMAP200800042A (it) Composizioni e metodi di impiego per anticorpi di dickkopf-1
LT2442791T (lt) Apiksabano vaisto formos
HUE065114T2 (hu) Monoklórtrifluorpropén vegyületek és készítmények és eljárások azok alkalmazásával
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0914300A2 (pt) composições e métodos para imunogenicidade intensificada de somatostatina
BRPI0913398A2 (pt) composição e métodos de adesivo para dentaduras

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.